Bio Essence Corp

OTC:BIOE

Pharmaceutical Preparations·IRVINE, CA

CEO

Yan Yin

Summary Financials

Revenue

$323,940

-47.9% YoY

FY 2024

Adj. EBITDA

-$340,797

-105.2% margin

FY 2024

Net Income

-$971,879

-300.0% margin

FY 2024

EPS (Diluted)

-$0.03

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$1,371

FY 2024

Total Debt

$56,481

FY 2024

Net Debt

$55,110

FY 2024

Enterprise Value

—

Debt / EBITDA

-0.2x

FY 2024

EV / EBITDA

—

Employees

—

Revenue

$323,940

-47.9% YoY

FY 2024

Adj. EBITDA

-$340,797

-105.2% margin

FY 2024

Net Income

-$971,879

-300.0% margin

FY 2024

EPS (Diluted)

-$0.03

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$1,371

FY 2024

Total Debt

$56,481

FY 2024

Net Debt

$55,110

FY 2024

Enterprise Value

—

Debt / EBITDA

-0.2x

FY 2024

EV / EBITDA

—

Employees

—